Roger Stupp, MD: May 7, 2018

NEW HOPE FOR INNOVATIVE TREATMENT OPTIONS IN BRAIN CANCER CARE 

**MAY IS BRAIN TUMOR AWARENESS MONTH** 

Roger Stupp, MD

Northwestern Medicine neuro-oncologist in Chicago, Illinois

 

 


In the last year, the deadliest and most aggressive form of cancer has been thrusted back in the headlines—glioblastoma. Nearly a decade ago Senator Edward Kennedy passed away from the disease. Meanwhile, Senator John McCain was diagnosed last July with the same type of brain cancer. Astonishingly an estimated 12,760 new cases of glioblastoma are predicted in 2018 according to the American Brain Tumor Association.

But how far have we come with treating this incurable disease.

In this radio interview, world-renowned brain tumor experts will discuss five new treatment options that have transformed quality of life and survival rates for patients with glioblastoma; NeuroBlate, immunotherapy, Gamma Knife surgery, Tumor Treating Fields and endoscopic endonasal tumor removal. Dr. James Chandler will be available to discuss innovative surgical treatment options for brain tumors while Dr. Roger Stupp will be available to provide insight about medical management of brain tumors including tumor treating fields.

A brain tumor is defined as an abnormal growth of tissue in the brain or central spine that can disrupt proper brain function. Glioblastoma is especially lethal due to the fact that surgical removal of the tumor may not be able to extract every single cancerous cell causing glioblastoma to reoccur. There are four distinct types of tumor cells in the brain: benign, malignant, primary and metastatic with over 120 types of brain and central nervous system tumors that exist. This makes choosing a highly-skilled team of surgeons who can diagnose and treat the patient affectively imperative.

 

For more information please visit braintumorinstitute.org 

 

MORE ABOUT DR. ROGER STUPP:

Roger Stupp trained in Internal Medicine in Switzerland and in Hematology/Oncology at the University of Chicago. He then worked over 17 years as a physician and researcher at the University of Lausanne, and from 2013 – 2017 as the Director of the Department of Oncology at the University Hospital in Zurich, Switzerland. Since April 2017 he holds an appointment as Division Chief of Neuro-Oncology and Co-Director of the Brain Tumor Institute and Associate Director for Strategic Initiatives of the Robert H. Lurie Comprehensive Cancer Center. Dr. Stupp has been a member of the European Organisation for Research and Treatment of Cancer (EORTC) since 1994, and serves as a member of the Board of Directors and Executive Committee since 2006, as their President from 2012 – 2017. Dr. Stupp’s research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. Roger Stupp is best known for his contributions in landmarks trials establishing temozolomide and, most recently tumor treating fields as the standard of care for glioblastoma patients. In 2017 he took new responsibilities as leader of medical neuro-oncology and cancer research within Northwestern Universities Robert H. Lurie Comprehensive Cancer Center and the Brain Tumor Institute. He remains dedicated to translational cancer research, scientific cooperation and believes in the importance of well-designed clinical trials conducted within academic cooperative groups.

Speak Your Mind

*